FY2026 EPS Estimates for WVE Increased by Cantor Fitzgerald

WAVE Life Sciences Ltd. (NASDAQ:WVE) – Cantor Fitzgerald increased their FY2026 earnings per share (EPS) estimates for WAVE Life Sciences in a research report issued on Tuesday, November 11th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the company will post earnings of ($1.26) per share for the year, up from their previous forecast of ($1.29). Cantor Fitzgerald has a “Overweight” rating and a $12.00 price objective on the stock. The consensus estimate for WAVE Life Sciences’ current full-year earnings is ($1.14) per share.

WAVE Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.02). The firm had revenue of $7.61 million during the quarter, compared to analysts’ expectations of $9.85 million.

Other equities research analysts have also issued reports about the stock. HC Wainwright restated a “buy” rating and issued a $22.00 price objective on shares of WAVE Life Sciences in a report on Wednesday, September 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of WAVE Life Sciences in a research report on Wednesday, October 8th. Canaccord Genuity Group initiated coverage on shares of WAVE Life Sciences in a research note on Monday, August 4th. They issued a “buy” rating and a $19.00 price target for the company. Wedbush raised their price objective on WAVE Life Sciences from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, B. Riley reiterated a “buy” rating on shares of WAVE Life Sciences in a report on Thursday, September 4th. Eleven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.73.

WAVE Life Sciences Price Performance

Shares of WVE opened at $6.67 on Thursday. The firm has a market cap of $1.06 billion, a P/E ratio of -7.41 and a beta of -1.44. The stock has a 50 day simple moving average of $7.43 and a two-hundred day simple moving average of $7.55. WAVE Life Sciences has a 1 year low of $5.28 and a 1 year high of $16.38.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of WVE. Federated Hermes Inc. raised its stake in WAVE Life Sciences by 678,144.7% during the third quarter. Federated Hermes Inc. now owns 3,750,693 shares of the company’s stock valued at $27,455,000 after buying an additional 3,750,140 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in shares of WAVE Life Sciences by 30.1% during the first quarter. Adage Capital Partners GP L.L.C. now owns 12,516,500 shares of the company’s stock valued at $101,133,000 after acquiring an additional 2,894,396 shares in the last quarter. Loomis Sayles & Co. L P increased its holdings in shares of WAVE Life Sciences by 35.3% during the second quarter. Loomis Sayles & Co. L P now owns 3,295,700 shares of the company’s stock valued at $21,422,000 after acquiring an additional 859,160 shares in the last quarter. Stempoint Capital LP raised its position in shares of WAVE Life Sciences by 902.2% in the 2nd quarter. Stempoint Capital LP now owns 900,338 shares of the company’s stock worth $5,852,000 after purchasing an additional 810,505 shares during the last quarter. Finally, Kennedy Capital Management LLC boosted its stake in WAVE Life Sciences by 1,489.5% in the 3rd quarter. Kennedy Capital Management LLC now owns 540,437 shares of the company’s stock worth $3,956,000 after purchasing an additional 506,437 shares in the last quarter. 89.73% of the stock is currently owned by institutional investors.

Insider Activity

In other WAVE Life Sciences news, CEO Paul Bolno sold 217,351 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $10.10, for a total transaction of $2,195,245.10. Following the transaction, the chief executive officer owned 121,000 shares in the company, valued at approximately $1,222,100. This represents a 64.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gregory L. Verdine sold 10,000 shares of the firm’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $10.00, for a total value of $100,000.00. Following the transaction, the director directly owned 285,217 shares of the company’s stock, valued at $2,852,170. This represents a 3.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 23.98% of the stock is owned by company insiders.

About WAVE Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.